Superworth

Zevra Therapeutics profit margin ZVRA

Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.

Net margin, 12 months
42.8%
Operating margin, 12 months
60.5%
Net margin on a year earlier
+38.6 pts
Peer median
11.2%

Over the twelve months to Jun 30, 2026, Zevra Therapeutics kept 42.8% of its revenue as net profit, with an operating margin of 60.5% and a gross margin of 95.5%.

Five years earlier its net margin was −42.1%.

The median for 10 large drugmakers of a similar size is 11.2%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY202578.2%−59.1%84.5%
FY2024n/an/a68.6%
FY2023n/an/a92.1%
FY2022n/an/a96.7%
FY2021−29.9%27.0%n/a
FY2020−96.0%−42.2%n/a
FY2019n/an/an/a
FY2018n/an/an/a
FY2017n/an/an/a
FY2016n/an/an/a
FY2015n/an/an/a
FY2014n/an/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY2642.8%+38.6 pts60.5%
Q1 FY26n/an/a−4.4%
Q4 FY2578.2%n/a−59.1%
Q3 FY2541.9%n/an/a
Q2 FY254.3%n/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY23n/an/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Zevra Therapeutics' size, closest first, today.

CompanyProfit margin
ZVRAZevra Therapeutics42.8%
IRWDIronwood Pharmaceuticals33.4%
PBYIPuma Biotechnology11.6%
CRMDCorMedix40.5%
ARVNArvinas2.9%
COLLCollegium Pharmaceutical5.9%
ABUSArbutus Biopharma84.2%
AMPHAmphastar Pharmaceuticals10.8%
OMEROmerosn/m
PCRXPacira BioSciences2.0%
ANABAnaptysbion/m
Peer median11.2%

Where Zevra Therapeutics ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Zevra Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.